Case number 1:22-cv-01611
Taiho Pharmaceutical Co., Ltd. et al v. Eugia Pharma Specialities, Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 4, 2024 | 21 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,456,399 B2; 10,960,004 B2. (Attachments: # 1 Stipulation of Dismissal)(ceg) (Entered: 04/04/2024) (0) |
| Apr 3, 2024 | 20 | SO ORDERED, re (168 in 1:19-cv-02309-JLH, 19 in 1:23-cv-01193-JLH, 19 in 1:22-cv-01611-JLH, 117 in 1:21-cv-00838-JLH) Stipulation and Order of Dismissal between Plaintiffs and Defendants Eugia Pharma Specialties Ltd., Aurobindo Pharma Ltd., and AurobindoPharma USA, Inc. Signed by Judge Jennifer L. Hall on 4/3/2024. Associated Cases: 1:19-cv-02309-JLH, 1:21-cv-00838-JLH, 1:22-cv-01611-JLH, 1:23-cv-01193-JLH(ceg) (Entered: 04/03/2024) (3) |
| Apr 2, 2024 | 19 | STIPULATION of Dismissal with Prejudice by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Whitesell, Angela) (Entered: 04/02/2024) (3) |
| Apr 6, 2023 | 18 | STIPULATION and [Proposed] Order to Extend Certain Scheduling Order Deadlines by Natco Pharma Ltd., Natco Pharma, Inc.. (Cragg, Tyler) (Entered: 04/06/2023) (6) |
| Feb 28, 2023 | 17 | SCHEDULING & CONSOLIDATION ORDER: Civil Action No. 21-838-CFC shall be the lead case and all future filings shall be made in Lead Case No. 21-838-CFC ONLY. Joinder of Parties due by 6/16/2023. Amended Pleadings due by 6/16/2023. Fact Discovery completed by 9/29/2023. Expert Discovery due by 2/29/2024. Signed by Judge Colm F. Connolly on 2/28/2023. Associated Cases: 1:21-cv-00838-CFC, 1:22-cv-01480-CFC, 1:22-cv-01611-CFC, 1:23-cv-00008-CFC(nmf) (Entered: 02/28/2023) (25) |
| Feb 27, 2023 | 15 | Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding the Parties' Joint Proposed Scheduling Order. (Balick, Steven) (Entered: 02/27/2023) (2) |
| Feb 27, 2023 | 16 | PROPOSED ORDER (Proposed Scheduling Order), by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 02/27/2023) (25) |
| Feb 13, 2023 | 14 | SO ORDERED, re (13 in 1:22-cv-01611-CFC, 16 in 1:22-cv-01480-CFC) STIPULATION TO EXTEND TIME proposed scheduling order to February 27, 2023, filed by Natco Pharma Ltd., Natco Pharma, Inc. Resetting Deadlines: Notice of Compliance deadline set for 2/27/2023. Signed by Judge Colm F. Connolly on 2/13/2023. Associated Cases: 1:22-cv-01480-CFC, 1:22-cv-01611-CFC(kmd) (Entered: 02/13/2023) (4) |
| Feb 10, 2023 | 13 | STIPULATION TO EXTEND TIME proposed scheduling order to February 27, 2023 - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Cragg, Tyler) (Entered: 02/10/2023) (4) |
| Jan 20, 2023 | 12 | ANSWER to 9 Answer to Complaint, Counterclaim by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 01/20/2023) (12) |
| Jan 12, 2023 | 11 | ORDER, having been assigned these cases which are listed as related to earlier filed cases that are currently proceeding on an agreed upon schedule entered by the Court; IT IS ORDERED that, on or before February 13, 2023, counsel for the parties shall confer regarding coordination of the cases and submit a proposed scheduling order to the Court or otherwise advise the Court that a separate scheduling conference is needed. ORDER, Setting Deadlines: ( Notice of Compliance deadline set for 2/13/2023.) Signed by Judge Colm F. Connolly on 1/12/2023. Associated Cases: 1:22-cv-01480-CFC, 1:22-cv-01611-CFC, 1:23-cv-00008-CFC(nmf) (Entered: 01/12/2023) (2) |
| Jan 3, 2023 | 9 | ANSWER to 1 Complaint, , COUNTERCLAIM against All Plaintiffs by Aurobindo Pharma Ltd., Eugia Pharma Specialities, Ltd., Aurobindo Pharma U.S.A., Inc..(Dorsney, Kenneth) (Entered: 01/03/2023) (30) |
| Jan 3, 2023 | 10 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma Limited, Corporate Parent Mviyes Pharma Ventures Private Limited for Eugia Pharma Specialities, Ltd.; Corporate Parent Aurobindo Pharma Limited for Aurobindo Pharma U.S.A., Inc. filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities, Ltd.. (Dorsney, Kenneth) (Entered: 01/03/2023) (2) |
| Dec 29, 2022 | 8 | SUMMONS Returned Executed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc..Aurobindo Pharma U.S.A., Inc. served on 12/29/2022, answer due 1/19/2023. (Balick, Steven) (Entered: 12/29/2022) (2) |
| Dec 28, 2022 | 7 | STANDING ORDER REGARDING BRIEFING IN ALL CASES. Associated Cases: 1:22-cv-01611-CFC et al.(kmd) (Entered: 12/28/2022) (2) |
| Dec 20, 2022 | 1 | Complaint* (1) |
| Dec 20, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs) (Entered: 12/20/2022) (3) |
| Dec 20, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: November 17, 2022. Date of Expiration of '399 Patent: February 3, 2037. Expiration of '004 Patent: February 3, 2037.Thirty Month Stay Deadline: 3/23/2023. (srs) (Entered: 12/20/2022) (2) |
| Dec 20, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,456,399 B2 ;10,960,004 B2. (srs) (Entered: 12/20/2022) (1) |
| Dec 20, 2022 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Taiho Pharmaceutical Co., Ltd. filed by Taiho Pharmaceutical Co., Ltd.. (srs) (Entered: 12/20/2022) (2) |
| Dec 20, 2022 | 6 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd., Corporate Parent Taiho Pharmaceutical Co., Ltd. for Taiho Oncology, Inc. filed by Taiho Oncology, Inc.. (srs) (Entered: 12/20/2022) (2) |
